For research use only. Not for therapeutic Use.
Phospholipase D (PLD) inhibitor (IC50 values of 20-25 nM for both PLD1 and PLD2) that rapidly blocks in vivo phosphatidic acid (PA) production with subnanomolar potency.
FIPI does inhibit PLD regulation of F-actin cytoskeleton reorganization, PIP2 availability, cell spreading, and chemotaxis, indicating potential utility for it as a therapeutic for autoimmunity and cancer metastasis.
| Catalog Number | I012639 |
| CAS Number | 1781834-93-2 |
| Molecular Formula | C23H24FN5O2.HCl |
| Purity | ≥95% |
| IUPAC Name | 5-fluoro-N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]-1H-indole-2-carboxamide;hydrochloride |
| InChI | InChI=1S/C23H24FN5O2.ClH/c24-16-5-6-18-15(13-16)14-20(26-18)22(30)25-9-12-28-10-7-17(8-11-28)29-21-4-2-1-3-19(21)27-23(29)31;/h1-6,13-14,17,26H,7-12H2,(H,25,30)(H,27,31);1H |
| SMILES | C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCNC(=O)C4=CC5=C(N4)C=CC(=C5)F.Cl |
| Reference | W. Su et al. 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. Mol. Pharmacol. 2009, 75, 437-446.
L. Monovich et al. Optimization of halopemide for phospholipase D2 inhibition. Bioorg. Med. Chem. Lett. 2007, 17, 2310-2311. |
